Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year and is the second leading cause of cancer death. 1 CRC occurs more …

The number of deaths from colorectal cancer in Japan continues to increase. Colorectal
cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Malignant liver tumours include a wide range of primary and secondary tumours. Although
surgery remains the mainstay of curative treatment, modern therapies integrate a variety of …

The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …

PURPOSE CALGB/SWOG 80405 was a randomized phase III trial that found no statistically
significant difference in overall survival (OS) in patients with first-line metastatic colorectal …

Background The interim analysis of the multicentre New EPOC trial in patients with
resectable colorectal liver metastasis showed a significant reduction in progression-free …